CLR 4001

Drug Profile

CLR 4001

Alternative Names: CJH 1; CLR4001; CRL 400

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator Clera
  • Class Antiparkinsonians
  • Mechanism of Action Dopamine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 05 Feb 2016 Phase-IIa development is ongoing in Canada
  • 01 Sep 2012 Phase-II clinical trials in Parkinson's disease in Canada (PO)
  • 07 Feb 2011 No development reported for Parkinson's disease in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top